Abstract
Treatment of infantile Pompe disease with recombinant human acid α-glucosidase has shown substantial improvement in survival, and in cardiac, motor and respiratory functions. We analyzed the outcome of all patients with infantile Pompe disease treated in the United Kingdom since the availability of the enzyme, using a questionnaire-based survey circulated to all treating centres. A total of 20 infants were treated from 2000 to 2009. Median ages at diagnosis and treatment were 5.75 months (range 0.25–31 months) and 6.5 months (0.5–32 months), respectively. Median duration of treatment was 31 months (1–102 months). Overall ventilator-free survival was 35% (7/20 infants), while 35% (7/20) died at a median age of 10 months (5.75–15 months) and 30% (6/20) were alive but ventilator-dependent. Endotracheal intubation for acute deterioration carried a high risk of failure of extubation and progression to long-term ventilation (LTV), but elective general anaesthesia, in contrast, was well tolerated. Overall outcome was worse than in the pivotal clinical trials; possible causes include later diagnosis and treatment in our patients and a higher incidence of infants at the severe end of the clinical spectrum. Careful consideration must be given to all possible outcomes, including LTV, before commencing enzyme replacement therapy in newly diagnosed infants.
Similar content being viewed by others
References
Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671–676
Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N et al (2007) Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology 68:99–109
Kishnani PS, Corzo D, Leslie N, Gruskin D, van der Ploeg A, Clancy JP, Parini R et al (2009) Pediatr Res 66:329–335
Kishnani PS, Goldenburg PC, DeArmey SL, Heller J, Benjamin D, Young S, Bali D et al (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26–33
Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, Arnold GL et al (2009) Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11:210–219
van den Hout HMP, Hop W, van Digglen OP, Smeitink JAM, Smit GPA, Poll-The BT, Bakker HD et al (2003) The natural course of infantile Pompe disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332–340
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by: Olaf Bodamer
Competing interest: None declared.
Rights and permissions
About this article
Cite this article
Chakrapani, A., Vellodi, A., Robinson, P. et al. Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J Inherit Metab Dis 33, 747–750 (2010). https://doi.org/10.1007/s10545-010-9206-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-010-9206-3